Malignant Melanoma With Braf V600e Mutation — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for malignant melanoma with braf v600e mutation. 60 active patents protecting 2 drugs from 2+ originators. First major cliff: 2026. Daily refresh.

2
Approved drugs
60
Active US patents
41/100
Avg vulnerability
$100M
Annual revenue covered

Originators in Malignant Melanoma With Braf V600e Mutation

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Gilead Sciences 54 patents Hoffmann La Roche 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating malignant melanoma with braf v600e mutation. Each bar = one year. Y-axis scaled to peak year (12 patents).

12
26
8
27
10
29
11
30
12
32
6
33
1
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Tybost
COBICISTAT
 Gilead Sciences 54 46 — 2026-08-27
Zelboraf
vemurafenib
 Hoffmann La Roche 6 35 $100M 2026-06-21

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8470818 Zelboraf method of use 85 2026-08-02
7176220 Tybost method of use 68 2026-08-27
7635704 Tybost method of use 68 2026-10-26
8148374 Tybost method of use 64 2029-09-03
8148374 Tybost method of use 64 2029-09-03
7176220 Tybost method of use 63 2026-08-27
7635704 Tybost method of use 63 2026-10-26
7176220 Tybost other 63 2027-02-27
7176220 Tybost other 63 2027-02-27
8981103 Tybost other 63 2027-04-26

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7700645 Tybost composition of matter 5 2026-12-26
7700645 Tybost composition of matter 5 2026-12-26
8981103 Tybost composition of matter 5 2026-10-26
8981103 Tybost composition of matter 5 2026-10-26
8741920 Zelboraf composition of matter 15 2030-07-27
7863288 Zelboraf composition of matter 15 2029-06-20
7700645 Tybost composition of matter 18 2026-12-26
10039718 Tybost formulation 25 2032-10-06
10039718 Tybost formulation 25 2032-10-06
10039718 Tybost formulation 25 2032-10-06

Related